Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 19.93 Million USD | -44.9% |
| 2022 | 31.11 Million USD | 22.95% |
| 2021 | 25.3 Million USD | 31.82% |
| 2020 | 19.19 Million USD | 418.08% |
| 2019 | 3.7 Million USD | 16.43% |
| 2018 | 3.18 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.11 Million USD | -3.85% |
| 2024 Q2 | 5.79 Million USD | 13.36% |
| 2023 Q3 | 5.55 Million USD | 29.33% |
| 2023 Q4 | 5.31 Million USD | -4.21% |
| 2023 FY | 17.14 Million USD | -44.9% |
| 2023 Q1 | 4.77 Million USD | -30.97% |
| 2023 Q2 | 4.29 Million USD | -10.15% |
| 2022 Q3 | 8.39 Million USD | -0.43% |
| 2022 Q2 | 8.43 Million USD | 14.49% |
| 2022 FY | 31.11 Million USD | 22.95% |
| 2022 Q1 | 7.36 Million USD | -28.04% |
| 2022 Q4 | 6.92 Million USD | -17.57% |
| 2021 Q2 | 4.97 Million USD | 25.67% |
| 2021 FY | 25.3 Million USD | 31.82% |
| 2021 Q3 | 6.14 Million USD | 23.53% |
| 2021 Q4 | 10.23 Million USD | 66.62% |
| 2021 Q1 | 3.95 Million USD | 11.09% |
| 2020 Q2 | 11.36 Million USD | 513.53% |
| 2020 Q4 | 3.56 Million USD | 47.44% |
| 2020 Q3 | 2.41 Million USD | -78.75% |
| 2020 FY | 19.19 Million USD | 418.08% |
| 2020 Q1 | 1.85 Million USD | -14.61% |
| 2019 Q1 | 387.3 Thousand USD | 0.0% |
| 2019 FY | 3.7 Million USD | 16.43% |
| 2019 Q4 | 2.16 Million USD | 146.69% |
| 2019 Q3 | 879.5 Thousand USD | 226.95% |
| 2019 Q2 | 269 Thousand USD | -30.54% |
| 2018 FY | 3.18 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -2915.477% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -115.141% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 33.52% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 70.305% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -25.856% |
| Better Therapeutics, Inc. | 38.26 Million USD | 47.887% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 50.996% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -60.895% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 41.085% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 42.069% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 81.617% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -1908.372% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 38.816% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 57.532% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -1541.516% |
| Molecular Templates, Inc. | 63.09 Million USD | 68.396% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -43.123% |
| NexImmune, Inc. | 28.16 Million USD | 29.212% |
| Orgenesis Inc. | 45.75 Million USD | 56.423% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 22.255% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -27059.339% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -23.499% |
| Scopus BioPharma Inc. | 11.71 Million USD | -70.205% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 95.059% |
| Statera Biopharma, Inc. | 28.82 Million USD | 30.837% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -5.337% |
| Trevena, Inc. | 38.41 Million USD | 48.092% |
| Vaxxinity, Inc. | 56.05 Million USD | 64.427% |
| Vaccinex, Inc. | 23.45 Million USD | 14.989% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -1804.462% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 60.667% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -174.094% |